Certara Announces Acquisition Agreement With Simcyp Limited

ST. LOUIS--(BUSINESS WIRE)-- Certara?, a leading provider of drug discovery and development software and scientific consulting services and a portfolio company of Vector Capital, today announced agreement to acquire Simcyp Limited. Simcyp is a UK-based, leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations. The agreement means Simcyp will join the Certara portfolio and provide key, extensible technologies that support Certara's translational science initiatives.

In making the announcement, Certara's President and Chief Executive Officer, Jim Hopkins said, "We're excited to add Simcyp to the Certara family of respected industry brands, currently anchored by Tripos and Pharsight. The capabilities offered by Simcyp's preclinical technologies, combined with our existing software products and scientific consulting services, will provide significant drug development advantages to our mutual and prospective clients. From a translational science perspective, Simcyp's preclinical simulation technologies, which include prediction of drug/drug interactions, fit perfectly between Certara's existing discovery and clinical research offerings, thus enabling an end-to-end solution. For example, this means broader capabilities to predict drug disposition as a function of molecular structure, and the ability to utilize a single unified suite of tools to facilitate preclinical and clinical PBPK and PKPD modeling and analysis."

"We're very pleased to be part of the Certara team," said John Evans, Managing Director at Simcyp. "This acquisition by Certara will allow Simcyp to focus on its core competence while drawing on the broader drug development expertise available within the Certara family. Clients from across the spectrum of drug discovery and development will have access to an expanded and integrated range of products and services, which will be enhanced by combining the attributes of Tripos, Simcyp, and Pharsight science and functionality."

About Certara

Certara? is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery, with Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation and scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.

About Simcyp

As a Certara portfolio company, Simcyp will continue to provide platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse). The technology allows pharmaceutical researchers to predict in vivo outcomes from routinely generated in vitro data, to fit Simcyp models to observed clinical data, and to assess inter-individual variability through ?real-life' simulations. This informs decision-making in drug development. Simcyp will also continue providing expert consultancy services, run educational workshops, and support academic and drug regulatory research through the provision of not-for-profit simulator licenses. For further information please visit www.simcyp.com.